Arxis Prices 40.5M Shares at $28.00
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy ARXS?
Arxis priced 40.5M shares at $28.00, at the high end of the $25.00-$28.00 target range. Goldman Sachs, Morgan Stanley and Jefferies are acting as joint book running managers for the offering. Arxis is a designer and manufacturer of proprietary, mission-critical electronic and mechanical engineered components and a portfolio company of Arcline Investment Management.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARXS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARXS
Wall Street analysts forecast ARXS stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 38.750
Low
Averages
High
Current: 38.750
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IPO Market Heats Up with $4.5 Billion Raised by Five Listings
- Record Fundraising: This week, five companies raised a total of $4.5 billion in IPOs, including two deals exceeding $1 billion, highlighting a significant uptick in market activity, particularly with Madison Air Solutions leading at $2.233 billion, reflecting strong demand for indoor air quality technologies.
- Strong Market Performance: Madison Air Solutions completed its IPO at the high end of pricing, achieving a market cap of $13.423 billion and a first-day return of 20%, indicating investor confidence in its air management technologies for data centers and commercial environments, which is expected to drive further market share growth.
- Biotech Breakthrough: Kailera Therapeutics raised $625 million, setting a record for US biotech IPOs with a market cap of $2.021 billion, as its lead candidate is currently in global Phase 3 trials, showcasing its potential in obesity treatment, with a first-day return of 63%.
- Growth in Defense Electronics: Arxis successfully raised $1.134 billion in its IPO, achieving a market cap of $11.633 billion; despite cyclical risks in aerospace and defense spending, its profitability and expanding free cash flow maintain its competitive edge, with a first-day return of 36%.
See More
Arxis Inc. Shares Surge 36% on Strong IPO Debut Raising $1.13 Billion
- Strong IPO Performance: Arxis Inc. shares surged 36% on their first day of trading on Nasdaq, rising from the IPO price of $28 to $38, indicating robust investor demand for its $1.13 billion expanded IPO, valuing the company at approximately $15.4 billion.
- Increased Offering Size: The company expanded its offering from the initially planned 37.7 million shares to 40.5 million shares, pricing at the top end of the $25 to $28 target range, reflecting strong market interest in the defense and aerospace sectors.
- Diverse Business Structure: According to regulatory filings, defense and space applications account for 47% of Arxis's projected 2025 revenue, while commercial aerospace contributes 23%, highlighting the company's broad exposure to both military and civil aviation markets, allowing it to capitalize on rising global defense spending.
- Positive Industry Trends: The listing of Arxis has attracted investor attention amid increasing global defense spending, particularly as U.S. policymakers are expected to prioritize the expansion and modernization of missile systems, further fueling investment enthusiasm for companies linked to military supply chains.
See More
Arxis Prices IPO at $28, Raising $1.13 Billion
- IPO Financing Size: Arxis priced its IPO at $28 per share for 40.5 million shares, raising $1.13 billion, reflecting strong market confidence in its business model and providing ample funds for future expansion.
- Market Positioning: Arxis focuses on aerospace, medical technology, and specialized industrial markets, designing and manufacturing critical electronic and mechanical engineering components, and the IPO will further solidify its market position in these high-growth sectors.
- Acquisition Expansion Strategy: Under Arcline Investment Management's support, Arxis has rapidly expanded through over 30 acquisitions since 2019, including the $1.8 billion purchase of rival Kaman in 2024, enhancing its competitive edge in the industry.
- Transaction Arrangements: The underwriters have a 30-day option to purchase an additional 6.075 million shares, potentially increasing the financing size, with shares expected to begin trading on Nasdaq on April 16, 2026, under the symbol 'ARXS'.
See More
Arxis Raises $1.1 Billion in Successful IPO at $28 per Share
- Significant Fundraising: Arxis successfully raised $1.1 billion by offering 40.5 million shares at $28 each, exceeding its initial plan of 37.7 million shares, indicating strong market confidence in its business.
- Cornerstone Investor Support: Key investors such as Capital Group, Janus Henderson Investors, and T. Rowe Price committed $400 million, representing 35% of the IPO, further solidifying market recognition of Arxis.
- Diverse Product Line: Arxis specializes in electronic and mechanical components for high-performance environments, with products including connectors, sensors, and precision mechanical parts, widely used in aerospace, defense, and medical technology, showcasing its strategic positioning in multiple high-growth markets.
- Acquisition Expansion Strategy: Since its formation in 2019, Arxis has completed 32 acquisitions, including Kaman Corporation, demonstrating its commitment and capability to accelerate market share growth through strategic acquisitions.
See More
IPO Market Heats Up with $4.5 Billion Raised by Five Listings
- Record Fundraising: This week, five companies raised a total of $4.5 billion in IPOs, including two deals exceeding $1 billion, highlighting a significant uptick in market activity, particularly with Madison Air Solutions leading at $2.233 billion, reflecting strong demand for indoor air quality technologies.
- Strong Market Performance: Madison Air Solutions completed its IPO at the high end of pricing, achieving a market cap of $13.423 billion and a first-day return of 20%, indicating investor confidence in its air management technologies for data centers and commercial environments, which is expected to drive further market share growth.
- Biotech Breakthrough: Kailera Therapeutics raised $625 million, setting a record for US biotech IPOs with a market cap of $2.021 billion, as its lead candidate is currently in global Phase 3 trials, showcasing its potential in obesity treatment, with a first-day return of 63%.
- Growth in Defense Electronics: Arxis successfully raised $1.134 billion in its IPO, achieving a market cap of $11.633 billion; despite cyclical risks in aerospace and defense spending, its profitability and expanding free cash flow maintain its competitive edge, with a first-day return of 36%.
See More
Arxis Inc. Shares Surge 36% on Strong IPO Debut Raising $1.13 Billion
- Strong IPO Performance: Arxis Inc. shares surged 36% on their first day of trading on Nasdaq, rising from the IPO price of $28 to $38, indicating robust investor demand for its $1.13 billion expanded IPO, valuing the company at approximately $15.4 billion.
- Increased Offering Size: The company expanded its offering from the initially planned 37.7 million shares to 40.5 million shares, pricing at the top end of the $25 to $28 target range, reflecting strong market interest in the defense and aerospace sectors.
- Diverse Business Structure: According to regulatory filings, defense and space applications account for 47% of Arxis's projected 2025 revenue, while commercial aerospace contributes 23%, highlighting the company's broad exposure to both military and civil aviation markets, allowing it to capitalize on rising global defense spending.
- Positive Industry Trends: The listing of Arxis has attracted investor attention amid increasing global defense spending, particularly as U.S. policymakers are expected to prioritize the expansion and modernization of missile systems, further fueling investment enthusiasm for companies linked to military supply chains.
See More
Arxis Prices IPO at $28, Raising $1.13 Billion
- IPO Financing Size: Arxis priced its IPO at $28 per share for 40.5 million shares, raising $1.13 billion, reflecting strong market confidence in its business model and providing ample funds for future expansion.
- Market Positioning: Arxis focuses on aerospace, medical technology, and specialized industrial markets, designing and manufacturing critical electronic and mechanical engineering components, and the IPO will further solidify its market position in these high-growth sectors.
- Acquisition Expansion Strategy: Under Arcline Investment Management's support, Arxis has rapidly expanded through over 30 acquisitions since 2019, including the $1.8 billion purchase of rival Kaman in 2024, enhancing its competitive edge in the industry.
- Transaction Arrangements: The underwriters have a 30-day option to purchase an additional 6.075 million shares, potentially increasing the financing size, with shares expected to begin trading on Nasdaq on April 16, 2026, under the symbol 'ARXS'.
See More
Arxis Raises $1.1 Billion in Successful IPO at $28 per Share
- Significant Fundraising: Arxis successfully raised $1.1 billion by offering 40.5 million shares at $28 each, exceeding its initial plan of 37.7 million shares, indicating strong market confidence in its business.
- Cornerstone Investor Support: Key investors such as Capital Group, Janus Henderson Investors, and T. Rowe Price committed $400 million, representing 35% of the IPO, further solidifying market recognition of Arxis.
- Diverse Product Line: Arxis specializes in electronic and mechanical components for high-performance environments, with products including connectors, sensors, and precision mechanical parts, widely used in aerospace, defense, and medical technology, showcasing its strategic positioning in multiple high-growth markets.
- Acquisition Expansion Strategy: Since its formation in 2019, Arxis has completed 32 acquisitions, including Kaman Corporation, demonstrating its commitment and capability to accelerate market share growth through strategic acquisitions.
See More
